Novel treatments for type 2 diabetes.

摘要

Jason Seewoodhary's article in the January Journal,' presents an optimistic view of the currently available alternatives to the standard treatments for type 2 diabetes. However, he makes no mention of the cost of these newer agents, nor the fact that long-term studies of their effectiveness, not just in reducing HbAic levels but in reducing morbidity and mortality, are lacking.